• Clinical Insights

What’s on the horizon: four emerging trends in the medication-assisted treatment space

Mar 6th, 2023

Keeping you informed as MAT evolves

Although medication-assisted treatment (MAT) programs are not new, they have recently gained renewed attention for their integral role in combating opioid use disorder (OUD), a chronic health condition that can be very life-threatening for those who live with it.

As the benefits of MAT programs are more widely realized, the regulations and restrictions on its use are continually evolving. There are several exciting recent trends and developments on the horizon, including:

  • Updated practice guidelines for the use of buprenorphine to treat opioid-use disorder
    • An X-Waiver is no longer required to treat patients with buprenorphine for OUD1
    • Going forward, prescriptions for buprenorphine will only require a standard DEA registration number
    • Subject to state law, physicians and other health care professionals with a regular DEA license can prescribe buprenorphine
  • Injectable treatment option – extended-release buprenorphine (Sublocade®)2
    • Approved for use as maintenance treatment of moderate to severe OUD in patients that have first initiated transmucosal buprenorphine
    • This treatment option is great for medication adherence
    • Does not require daily dosing
    • One monthly injection delivers a continuous release of medication throughout the month
  • Boston Medical Center MAT App (BMC MAT app) provides clinical guidance to help providers get up to speed on MAT administration3
    • This app is designed for providers new to the MAT space
    • Contains up-to-date guidelines and studies that can help with decision making
  • Telemedicine MAT programs have been proven to be equally as successful as in person treatment (per Maryland study)4

Ready to get started?

Interested in learning more about how medication-assisted treatment can help support your consumers? Genoa can help. Contact us today and we’ll be in touch.

"*" indicates required fields

Does your organization currently partner with Genoa?*
This field is for validation purposes and should be left unchanged.

Recent Posts

  • Blog Post
Genoa Pharmacist faces winter snowstorm to deliver consumers’ medications

When Watertown, New York, Pharmacist Meredith Sullivan made the call to close her pharmacy in preparation for an incoming snowstorm on Friday, Dec. 23, she wondered how the pharmacy’s closure...

  • Pharmacy Openings
Announcing three new pharmacy openings!

We’re excited to announce the opening of three pharmacies last month. We welcome all new pharmacy staff to the team and are excited to partner with these organizations to serve...

  • Clinical Insights
Frequently asked questions: buprenorphine-containing products

Information and sources on buprenorphine-containing products were taken from www.sublocade.com and www.suboxone.com.

  • Clinical Insights
What’s on the horizon: four emerging trends in the medication-assisted treatment space

1X-Waiver no longer need to treat opioid use disorder. (2023, January 13). ACEP. 2. Sublocade. 3.BMC launces app to help providers treat patients with opioid use disorder. (2021, March 22)....